BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 29751842)

  • 1. PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.
    Zschaeck S; Lohaus F; Beck M; Habl G; Kroeze S; Zamboglou C; Koerber SA; Debus J; Hölscher T; Wust P; Ganswindt U; Baur ADJ; Zöphel K; Cihoric N; Guckenberger M; Combs SE; Grosu AL; Ghadjar P; Belka C
    Radiat Oncol; 2018 May; 13(1):90. PubMed ID: 29751842
    [No Abstract]   [Full Text] [Related]  

  • 2. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.
    Dewes S; Schiller K; Sauter K; Eiber M; Maurer T; Schwaiger M; Gschwend JE; Combs SE; Habl G
    Radiat Oncol; 2016 May; 11():73. PubMed ID: 27229485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
    Ceci F; Castellucci P; Fanti S
    Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of prostate-specific membrane antigen positron emission tomography on the decision-making of radiation oncologists.
    Shakespeare TP
    Radiat Oncol; 2015 Nov; 10():233. PubMed ID: 26582424
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective.
    Debnath S; Zhou N; McLaughlin M; Rice S; Pillai AK; Hao G; Sun X
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
    Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
    Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
    Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
    Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
    Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Green MA; Hutchins GD; Bahler CD; Tann M; Mathias CJ; Territo W; Sims J; Polson H; Alexoff D; Eckelman WC; Kung HF; Fletcher JW
    Mol Imaging Biol; 2020 Jun; 22(3):752-763. PubMed ID: 31429050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-Body Integrated [
    Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
    Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
    Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
    BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
    Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
    Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pattern of failure in prostate cancer previously treated with radical prostatectomy and post-operative radiotherapy: a secondary analysis of two prospective studies using novel molecular imaging techniques.
    Rowe LS; Harmon S; Horn A; Shankavaram U; Roy S; Ning H; Lindenberg L; Mena E; Citrin DE; Choyke P; Turkbey B
    Radiat Oncol; 2021 Feb; 16(1):32. PubMed ID: 33568190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer.
    Farolfi A; Calderoni L; Mattana F; Mei R; Telo S; Fanti S; Castellucci P
    J Nucl Med; 2021 May; 62(5):596-604. PubMed ID: 33712536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of
    Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
    J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
    Barrio M; Fendler WP; Czernin J; Herrmann K
    Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
    Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
    Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An
    Dietlein F; Hohberg M; Kobe C; Zlatopolskiy BD; Krapf P; Endepols H; Täger P; Hammes J; Heidenreich A; Neumaier B; Drzezga A; Dietlein M
    J Nucl Med; 2020 Feb; 61(2):202-209. PubMed ID: 31324713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.